文献速递糖尿病

在DPT-1和TN07临床试验中,进展为1型糖尿病与HLA-DQA1-B1异二聚体的特定残基密切相关

Progression to type 1 diabetes in the DPT-1 and TN07 clinical trials is critically associated with specific residues in HLA-DQA1-B1 heterodimers.
PubMed 文献 · Diabetologia · 2024-10-01

该研究基于DPT-1和TN07临床试验中1216名参与者的高分辨率HLA-DQA1和DQB1基因型,采用分层单倍型关联分析(HOH)结合Cox回归,探究与1型糖尿病从1期或2期进展至3期相关的氨基酸残基及结构。研究发现异二聚化增加了细胞水平的遗传多样性,并识别出α链8个和β链6个氨基酸残基参与贡献DQ与1型糖尿病进展的关联。

要点

  • 异二聚化使43种实际观察到的单倍型扩展为186种可能的异二聚体。
  • 异二聚化使若干中性单倍型(DQ2.2、DQ2.3、DQ4.4)转变为风险单倍型。
  • 识别出α链8个和β链6个氨基酸残基贡献DQ与1型糖尿病进展的关联。

核心结论

  • 这些结果揭示了DQ在个体残基及相关蛋白结构水平对1型糖尿病进展的贡献,为免疫机制提供线索并为治疗策略开发提供新方向。

研究设计与样本

  • 研究纳入DPT-1和TN07临床试验中1216名参与者的高分辨率DQA1和DQB1基因型,采用分层单倍型关联分析(HOH),以Cox回归量化DQ与1型糖尿病发病时间的关联。

主要发现

  • 异二聚化使细胞水平遗传多样性从43种实际观察到的单倍型增加至186种可能的异二聚体。
  • 异二聚化使若干中性单倍型(DQ2.2、DQ2.3和DQ4.4)转变为风险单倍型(DQ2.2/2.3-DQ4.4和DQ4.4-DQ2.2)。
  • HOH识别出α链8个氨基酸(-16α、-13α、-6α、α22、α23、α44、α72、α157)和β链6个氨基酸(-18β、β9、β13、β26、β57、β135)贡献DQ与1型糖尿病进展的关联。
  • 相关特定氨基酸涉及信号肽(负号,可能与表达水平连锁)、α1β1结构域抗原结合槽的1、4和9口袋以及αβ异二聚体的推定同二聚化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this work was to explore molecular amino acids (AAs) and related structures of HLA-DQA1-DQB1 that underlie its contribution to the progression from stages 1 or 2 to stage 3 type 1 diabetes. METHODS: Using high-resolution DQA1 and DQB1 genotypes from 1216 participants in the Diabetes Prevention Trial-Type 1 and the Diabetes Prevention Trial, we applied hierarchically organised haplotype association analysis (HOH) to decipher which AAs contributed to the associations of DQ with disease and their structural properties. HOH relied on the Cox regression to quantify the association of DQ with time-to-onset of type 1 diabetes. RESULTS: By numerating all possible DQ heterodimers of α- and β-chains, we showed that the heterodimerisation increases genetic diversity at the cellular level from 43 empirically observed haplotypes to 186 possible heterodimers. Heterodimerisation turned several neutral haplotypes (DQ2.2, DQ2.3 and DQ4.4) to risk haplotypes (DQ2.2/2.3-DQ4.4 and DQ4.4-DQ2.2). HOH uncovered eight AAs on the α-chain (-16α, -13α, -6α, α22, α23, α44, α72, α157) and six AAs on the β-chain (-18β, β9, β13, β26, β57, β135) that contributed to the association of DQ with progression of type 1 diabetes. The specific AAs concerned the signal peptide (minus sign, possible linkage to expression levels), pockets 1, 4 and 9 in the antigen-binding groove of the α1β1 domain, and the putative homodimerisation of the αβ heterodimers. CONCLUSIONS/INTERPRETATION: These results unveil the contribution made by DQ to type 1 diabetes progression at individual residues and related protein structures, shedding light on its immunological mechanisms and providing new leads for developing treatment strategies. DATA AVAILABILITY: Clinical trial data and biospecimen samples are available through the National Institute of Diabetes and Digestive and Kidney Diseases Central Repository portal ( https://repository.niddk.nih.gov/studies ).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Zhao LP, Papadopoulos GK, Skyler JS, et al. Progression to type 1 diabetes in the DPT-1 and TN07 clinical trials is critically associated with specific residues in HLA-DQA1-B1 heterodimers. Diabetologia. 2024. PMID: 39354095. doi:10.1007/s00125-024-06274-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。